Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

It said that 95% of people with cystic fibrosis in England will now be eligible for modulator therapy. The new drug, also ...